SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending due to positive reactions to earnings and the acquisition of Ask Sage, with investors focusing on the potential for government contracts and long-term growth. The community is discussing the company's prospects as a "mini PLTR" and anticipating a rise in stock price, while also debating the impact of potential dilution.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave's upcoming earnings are driving significant discussion, with debates around whether strong growth and key partnerships with NVIDIA, Meta, and OpenAI will outweigh concerns about profitability and slowed growth. Community sentiment is mixed, as some highlight the company's leadership in deploying next-gen AI infrastructure and its massive revenue backlog, while others express skepticism regarding negative net income and heavy capital expenditure.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending downwards amidst concerns about its high valuation relative to revenue, especially after a recent earnings report revealed a GAAP net loss. Community members are discussing whether the company can justify its valuation given its revenue and comparing it unfavorably to competitors like D-Wave, while some suggest an offering may be imminent. The stock's movement is also being watched in relation to the broader quantum computing sector and potential government funding.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors digest recent earnings, which included a revenue beat and record gross margins, alongside news of the Neutron rocket program's progress and a Q1 2026 arrival at Launch Complex 3. While some express concern over the Neutron launch potentially being pushed to late 2026, many bulls see this as a buying opportunity, citing the company's strong existing revenue and significant backlog of launch contracts. The community is actively debating the long-term impact of the Neutron update and its potential for a gamma squeeze given a substantial short interest.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors digest recent earnings and a strategic pivot towards High-Performance Computing (HPC) and AI hosting, especially the Abernathy Joint Venture backed by Google. Community chatter highlights confidence in management's execution and future potential, with some anticipating analyst upgrades and new contracts before year-end. Despite mixed reactions to earnings, TeraWulf's AI infrastructure and partnerships are central to ongoing discussions.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark (CLSK) is trending amid discussions about a recent convertible note offering and its potential implications for the company's AI strategy. While some investors express concerns about dilution and debt, others view the offering as a bullish move to fund expansion into AI data centers and execute share buybacks. The community is actively debating whether the financing will ultimately benefit the company and drive future growth in the competitive mining sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await topline results from its Phase 3 HOPE-3 trial for Duchenne muscular dystrophy, expected in the coming weeks. Community discussion revolves around the potential for the data to support a BLA resubmission and approval, with some speculating on the timing of the data release and its impact on a possible short squeeze.  Optimism is fueled by positive data from earlier trials, though concerns exist regarding FDA flexibility and the potential for mixed results.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors discuss the potential impact of upcoming launches and significant government contracts on the company's future. Community talking points also revolve around the company's substantial cash reserves and commercialization efforts, despite recent revenue misses. The long-term potential of ASTS in the space-based cellular connectivity sector is a key focus.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto Inc. is trending due to a significant price surge, fueled by the completion of its acquisition of Damora Therapeutics and a substantial funding round. Community discussions revolve around the potential for a short squeeze, given the stock's low float and high cost to borrow, with some traders eyeing ambitious price targets. Comparisons to other high-flying stocks and potential catalysts related to their pipeline are also being actively discussed.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors anticipate upcoming earnings, drawing comparisons to competitor CRWV's recent performance. Community members are weighing the potential impact of data center buildout timelines and new deals on NBIS's revenue and growth guidance. Some traders are expressing concerns about broader market factors and potential pullbacks, while others remain bullish on the company's long-term prospects in the AI infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Has Positive Estimate for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright increased their FY2025 earnings estimates for BioCryst Pharmaceuticals in a research note issued to...

Citizens Jmp Has Lowered Expectations for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

Citizens Jmp reduced their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a "market outperform" rating for the company in a research note on Wednesday...

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?

Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to...

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

RBC Capital, Jefferies, and TD Cowen raised their price targets on BioCryst after the company announced plans to acquire Astria Therapeutics in a $700 million deal, with analysts calling the sell-off overdone and the combination strategically sound.<a href="https://stocktwits.com/symbol/BCRX">BioCryst shares</a> fell 8.8% to $6.42 on Tuesday, marking their fourth straight session of losses and the biggest single-day drop in nearly eight months, before edging up 1% in after-hours trading.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/ATXS">Astria Therapeutics’ stock</a> jumped 37.1% to $11.61 on Tuesday, its best day in nearly five years and highest level in almost a year, extending gains for a second straight session.RBC Capital raised its price target on BioCryst Pharmaceuticals to $15 from $14 and kept an 'Outperform' rating, saying Tuesday’s weakness in the stock presents a “compelling buying opportunity.” The firm said its confidence increased following BioCryst’s acquisition of Astria Therapeutics and discussions with management, adding that the deal sets up their franchise even better.Jefferies also raised its target on BioCryst to $15 from $14 while maintaining a 'Buy' rating. Analyst Maury Raycroft said the valuation reflects a discount due to a crowded hereditary angioedema (HAE) landscape, potential clinical and regulatory risks, and the need for FTC clearance, but added that the acquisition structure, under which Astria shareholders will own about 15% of the combined company, makes competing bids less likely.Meanwhile, TD Cowen reinstated coverage of BioCryst with a 'Buy' rating and a $30 price target, citing the company’s plan to acquire Astria’s Phase 3 injectable HAE prophylaxis candidate navenibart. The firm said navenibart, a plasma kallikrein inhibitor with strong proof of concept and high key opinion leader interest, is “de-risked.”&nbsp;BioCryst said on Tuesday that it will acquire Astria for $13 per share, valuing the company at about $700 million in enterprise value. The transaction, approved by both boards, is expected to close in the first quarter of 2026. BioCryst will finance the $8.55-per-share cash portion through a mix of existing cash and a new $550 million facility from Blackstone, with the rest paid in BioCryst stock.Astria’s navenibart, designed for quarterly or semi-annual injections, could expand BioCryst’s reach in the HAE market by complementing its existing oral therapy. BioCryst CEO Jon Stonehouse said the deal enables the company to “build out a comprehensive portfolio” that meets patient needs regardless of treatment preference.On Stocktwits, retail sentiment for both BioCryst and Astria was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said they had grown more positive on the Astria deal, noting that if the acquired asset is approved, it could make BioCryst’s revenue growth sustainable for years, which would help the company’s valuation even if some concerns remain.<stembedurl>https://stocktwits.com/luvpizza2/message/632344600</stembedurl>Another bullish user said the stock’s performance looked solid despite dilution, arguing that using undervalued shares to acquire a high-potential growth asset like Astria was a smart strategic move and could significantly boost BioCryst’s long-term worth.<stembedurl>https://stocktwits.com/Uptrending21/message/632308543</stembedurl>While BioCryst’s stock has declined 15% so far in 2025, Astria’s stock has risen 30% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

While BioCryst’s stock (BCRX) has declined 15% so far in 2025, Astria’s stock (ATXS) has risen 30% over the same period. (Photo credit: Getty Images)

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play

The deal, valued at $700 million and backed by new Blackstone financing, is expected to close in early 2026.

Equity

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

$NVDA

$MSFT

$AAPL

$GOOGL

Which of these Mag 7 stocks are you most bullish on right now?

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.